Rhythm Pharmaceuticals Inc (RYTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has a cash flow conversion efficiency ratio of -0.183x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.39 Million) by net assets ($139.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Rhythm Pharmaceuticals Inc (RYTM) market capitalisation for the company's overall valuation and market capitalisation.
Rhythm Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rhythm Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore RYTM cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cirrus Logic Inc
NASDAQ:CRUS
|
0.029x |
|
Marfrig Global Foods S.A.
SA:MRFG3
|
0.234x |
|
Railway Signal Communication Ltd
SHG:688009
|
0.013x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
|
Australian Foundation Investment Company Ltd
AU:AFI
|
0.012x |
|
Bank of Changsha Co Ltd
SHG:601577
|
1.054x |
|
WPG Holdings Ltd
TW:3702
|
-0.598x |
|
Shan Dong Sun Paper Industry Joint Stock Co Ltd
SHE:002078
|
0.046x |
Annual Cash Flow Conversion Efficiency for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025. View Rhythm Pharmaceuticals Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $139.07 Million | $-115.67 Million | -0.832x | -20.19% |
| 2024-12-31 | $164.55 Million | $-113.88 Million | -0.692x | +13.71% |
| 2023-12-31 | $169.76 Million | $-136.16 Million | -0.802x | -22.21% |
| 2022-12-31 | $264.26 Million | $-173.43 Million | -0.656x | -27.72% |
| 2021-12-31 | $284.15 Million | $-146.00 Million | -0.514x | +29.85% |
| 2020-12-31 | $166.53 Million | $-121.98 Million | -0.732x | -67.69% |
| 2019-12-31 | $281.02 Million | $-122.75 Million | -0.437x | -73.34% |
| 2018-12-31 | $246.26 Million | $-62.06 Million | -0.252x | -23.85% |
| 2017-12-31 | $144.79 Million | $-29.46 Million | -0.203x | +93.61% |
| 2016-12-31 | $7.30 Million | $-23.22 Million | -3.182x | -1359.47% |
| 2015-12-31 | $32.00 Million | $-6.98 Million | -0.218x | -101.04% |
| 2014-12-31 | $-358.00K | $-7.51 Million | 20.972x | +6190.74% |
| 2013-12-31 | $-57.46 Million | $-19.16 Million | 0.333x | -32.16% |
| 2012-12-31 | $-36.28 Million | $-17.83 Million | 0.491x | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more